AMPH Q3 2023 Earnings — Amphastar Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AMPHAmphastar Pharmaceuticals, Inc.

$894M

Q3 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$181M+50.3% YoY

Gross Profit

$108M60.0% margin

Operating Income

$73M40.3% margin

Net Income

$49M27.3% margin

EPS (Diluted)

$0.91

QoQ Revenue Growth

+23.9%

Cash Flow

Operating Cash Flow

$64M

Free Cash Flow

$54M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$1.5B

Total Liabilities

$949M

Stockholders' Equity

$595M

Cash & Equivalents

$267M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$181M	$120M	+50.3%
Gross Profit	$108M	$59M	+85.3%
Operating Income	$73M	$23M	+212.9%
Net Income	$49M	$16M	+210.1%

Revenue Segments

Product revenues, net

$152M84%

Other revenues

$29M16%

Geographic Segments

UNITED STATES

$178M99%

FRANCE

$2M1%

CHINA

$833,0000%